Cingulate Inc. Common Stock
CINGStock
$4.43−0.42%52W
Market Cap$61.82M
P/E—
Div yield—
Beta-0.92
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.03%
Price vs S&P 500 (4W)-4.07%
VGM Score42.81
Market Capitalization$61.82M
Earnings Surprise History
Q1 26-0.95est. -0.46
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.11
4.10
4.10
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CINGCingulate Inc. Common Stock | — | — | C | $4.43 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Cingulate Inc is a clinical-stage biopharmaceutical company developing treatments using its proprietary precision timed-release drug delivery platform. The company focuses on ADHD and anxiety disorders, where less frequent dosing could improve patient outcomes and medication adherence. Cingulate is also evaluating additional therapeutic applications for its platform technology.